The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.
Check Out Our Latest Analysis on United Therapeutics United Therapeutics Stock Down 1.6 % UTHR stock opened at $313.60 on Wednesday. United Therapeutics has a 52-week low of $221.53 and a 52-week ...
United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million.
United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 04, 2025--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James ...
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 04, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that ...
BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm thinks the challenges to owning United in 2025 are ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Molecular Partners (MOLN – Research Report), United Therapeutics (UTHR – Research Report) and Universal ...
Investors in United Therapeutics Corp (Symbol: UTHR) saw new options become available this week, for the November 21st expiration. One of the key inputs that goes into the price an option buyer is ...
We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results